ClinicalTrials.gg
RecruitingNCT06872255VADYSMAUpdated Nov 12, 2026

Per-oral Endoscopic Myotomy (POEM) in Patients With Postfundplication Dysphagia

An interventional study of Per Oral Endoscopic Myotomy (POEM) in Dysphagia, Dysphagia, Esophageal and Healthy, sponsored by Institute for Clinical and Experimental Medicine. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Institute for Clinical and Experimental Medicine · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 12, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Laparoscopic fundoplication represents the standard antireflux procedure, when conservative measures fail. However, any type of fundoplication may be accompanied by adverse events. Postfundoplication dysphagia (PFD) may hamper results of anti-reflux surgery. Endoscopic pneumatic dilation has been considered as the first line treatment option for persistent PFD. However, studies have not confirmed its effectiveness in this indication. Peroral endoscopic myotomy (POEM) became a standard treatment for the management of esophageal achalasia and moreover has also been assessed in a small cohort of patients with refractory PFD and some patients achieved significant treatment success. The investigators plan to perform a prospective international cohort multicenter study assessing the efficacy of POEM in patients with persistent and severe PFD.

02

Conditions studied

  • Dysphagia
  • Dysphagia, Esophageal
  • Healthy

Browse trials for

03

In context

Deglutition Disorders

875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.

This study's planned enrollment of 30 is below the median of 60 across 581 interventional studies indexed under Deglutition Disorders.

Browse Deglutition Disorders studies →

Lead sponsor

Institute for Clinical and Experimental Medicine is the lead sponsor of 61 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients after laparoscopic fundoplication procedure by Nissen (total, 360°), Dor (anterior, 180°) or Toupet (posterior, 270°) for gastroesophageal reflux disease no later than 10 years before enrolment.
  2. (> 6 months) and severe dysphagia after fundoplication procedure defined as an Eckardt score ≥3 and Mellow - Pinkas score ≥2 at baseline.
  3. X-ray (contrasted radiographic examination of the esophagus) characterized by both: a.) tapered narrowing of the distal esophagus and GEJ; b.) partial/total stagnation of the contrast solution above the GEJ
  4. Endoluminal planimetry: EGJ-DI \< 3 mm2/mmHg (with 40ml)
  5. Age above 18 years
  6. Signed form

Exclusion criteria

Exclusion Criteria:

  1. No previous attempt with at least one prokinetic drug
  2. Previous esophageal myotomy (open, laparoscopic or endoscopic)
  3. Primary esophageal motility disorder (achalasia etc.)
  4. Active erosive esophagitis
  5. Active peptic ulcer disease
  6. Esophageal stricture (peptic, malignant, other)
  7. Partial or complete supradiaphragmatic migration of the wrap and/or stomach (Hinder Type III - IV), Large hiatal hernia more than 5 cm
  8. Known eosinophilic esophagitis
  9. Severe coagulopathy
  10. Esophageal or gastric varices
  11. Advanced liver cirrhosis (Child B or Child C)
  12. Pregnancy or puerperium
  13. Malignant or pre-malignant esophageal diseases (dysplasia): patients with a history of such disease after its cure are eligible for enrolment
  14. Any other condition, which in the opinion of the investigator would interfere with study requirements
  15. Known gastroparesis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    POEM arm

    Patients, who will undergo peroral endoscopic myotomy for postfundoplication dysphagia

    Procedure: Per Oral Endoscopic Myotomy (POEM)

Interventions

  • ProcedurePer Oral Endoscopic Myotomy (POEM)

    All procedures will be performed by an experienced endoscopist, with a sufficient experience in "third space" endoscopy (at least 100 POEMs) under general anesthesia (internal preoperative examination is necessary) with a high-definition endoscope, fitted with a plastic distal attachment. Before the procedure, the patients will be administered intravenous antibiotics. Exclusively CO2 will be used for insufflation. POEM will be performed in a similar way as in patients with achalasia - the procedure consists of 4 steps: (1) mucosal incision and tunnel entry, (2) submucosal tunneling, (3) myotomy, and (4) closure of the mucosal entry with endoscopic clips or other closure devices. Perioperative protocol might differ according the usual way of performing POEM in a given center.

06

What researchers measure

Primary outcomes

  1. Efficacy POEM in patients with postfundoplication dysfagia

    The primary outcome will be proportion of patients with treatment success defined as Eckardt score ≤ 2 and its decrease by at least 1 point after POEM at 6 months

    Time frame: 6 months

Secondary outcomes

  1. Eckardt score

    The Eckardt score is the grading system used for the evaluation of severity of symptoms in patients with esophageal achalasia. Four symptoms are assessed (dysphagia, regurgitation, chest pain and weight loss) and their severity ranges from 0 (no symptom) to 3 (with every meal). Total score is their sum and ranges from 0 to 12

    Time frame: At baseline, 3, 6 and 12 months

  2. Mellow - Pinkas score

    The Mellow - Pinkas score is used to assess dysphagia grade before and after the interventions. Total score ranges from 0 to 3 (0 = able to eat normal diet, 1 = able to swallow some solid foods, 2 = able to swallow only semi solid foods, 3 = able to swallow liquids only)

    Time frame: At baseline, 3, 6 and 12 months

  3. PAGI-QOL score (Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life)

    The PAGI-QoL questionnaire contains of 30 items with five subscales: (1) daily activities; (2) clothing; (3) diet/food habits; (4) relationship; and (5) psychological well-being and distress. Each item is scored on a 6-point Likert scale, with response options ranging from 0 (none) to 5 (severe problem all of the time). Subscale scores are calculated by averaging the item responses. A total score is calculated by averaging subscale scores. Higher score means impairment in quality of life.

    Time frame: At baseline, 3, 6 and 12 months

  4. GERD-RHQL score (Gastroesophageal Reflux Disease Health-related Quality of Life)

    The GERD-HRQL questionnaire was developed and validated to measure changes of typical GERD symptoms such as heartburn and regurgitation in response to surgical or medical treatment. Higher (greater) possible score means worst symptoms - ranging from 0 to 75.

    Time frame: At baseline, 3, 6 and 12 months

  5. Integrated Relaxation Pressure (IRP)

    High resolution manometry - Median IRP recorded from 10 supine swallows, measured in mmHg. A value \>15 mmHg indicates EGJ outflow obstruction.

    Time frame: At baseline, at 6 months

  6. Endoluminal planimetry (Endoflip)

    Pyloric distensibility measured by impedance planimetry (EndoFLIP device)

    Time frame: At baseline, ať 6 months

  7. Esophagogram

    Esophagogram provides valuable information of the fundoplication, better appreciate a paraesophageal hernia and information on esophageal emptying. Patients will be advised overnight fasting prior to timed barium esophagogram. A contrast agent (e.g. barium, usually 100 to 250 mL) is ingested orally within 15-20 seconds. Left posterior oblique X-ray will be taken 2 and 5 minutes after contrast agent ingestion. Maximum esophageal width and column hights will be recorded at 2 and 5 minutes.

    Time frame: At baseline, at 6 months

  8. Eckardt score

    The Eckardt score is used to assess the severity of achalasia symptoms. It is based on the four main symptoms of achalasia: dysphagia, regurgitation, chest pain and weight loss. Each symptom has four levels of severity: none = 0 point, occasional = 1 point, daily = 2 points, each meal = 3 points. The sum of the points gives the final score. Final score scale: 0 (best) - 12 (worst). Treatment success is defined as a decrease of Eckardt score by at least 1 point and an overall Eckardt score ≤ 2.

    Time frame: At baseline, 3 and 12 months

  9. GERD

    Presence of reflux esophagitis based on endoscopy findings.

    Time frame: At baseline, 3, 6 and 12 months

  10. Esophageal 24h-Hour pH metry

    An esophageal pH test measures how often stomach acid enters to the esophagus. It also measures how long the acid stays there. The test involves placing a catheter into the esophagus. The catheter or device will measure an acid level (known as pH level) for 24 hours. Post-POEM Esophageal acid exposure (DeMeester score, proportion of time with pH below 4)After

    Time frame: At 3 months after procedure

  11. PPI/H2 antagonists

    PPI's and/or H2 antagonists use before and after procedure (POEM).

    Time frame: At baseline, 3, 6 and 12 months

07

Study locations

2 of 3 sites recruiting
  • St. Anne's University Hospital Brno, Czech Republic
    Brno, 60200, Czechia
    Recruiting
  • Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava and University Hospital Martin,
    Martin, Slovakia 03601, Slovakia
    Recruiting
  • University Hospital Trnava
    Trnava, 91701, Slovakia
    Not yet recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jun 2027, 26 months after the start.

Of 290 non-industry interventional studies with no phase under Deglutition Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 26 months is above that.

Counting every sponsor, half of 299 studies reached it within 21 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Mar 12, 2025
StartActual
Apr 1, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
1 site added. University Hospital Trnava is now Not yet recruiting
Show site
  • Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava and University Hospital Martin, · Martin, Slovakia
Nov 12, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedEfficacy and safety of POEM in patients with postfundoplication dysfagiaTime frame: 6 months
Nov 12, 2026
Secondary outcomes
10 time frame changed
What changed in the outcomes
  • Time frameEckardt scoreAt baseline and after 3, 6 and 12 months → At baseline, 3, 6 and 12 months
  • Time frameMellow - Pinkas scoreAt baseline and after 3, 6 and 12 months → At baseline, 3, 6 and 12 months
  • Time framePAGI-QOL score (Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life)At baseline and after 3, 6 and 12 months → At baseline, 3, 6 and 12 months
  • Time frameGERD-RHQL score (Gastroesophageal Reflux Disease Health-related Quality of Life)At baseline and after 3, 6 and 12 months → At baseline, 3, 6 and 12 months
  • Time frameIntegrated Relaxation Pressure (IRP)At baseline and after 6 months → At baseline, at 6 months
  • Time frameEndoluminal planimetry (Endoflip)At baseline and after 6 months → At baseline, ať 6 months
  • Time frameEsophagogramAt baseline and after 6 months → At baseline, at 6 months
  • Time frameEckardt score#2At and after 3 and 12 months → At baseline, 3 and 12 months
  • Time frameGERDAt baseline and after 3, 6 and 12 months → At baseline, 3, 6 and 12 months
  • Time framePPI/H2 antagonistsAt baseline and after 3, 6 and 12 months → At baseline, 3, 6 and 12 months
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    1 site added. University Hospital Trnava is now Not yet recruiting
    Show site
    • Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava and University Hospital Martin, · Martin, Slovakia
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedEfficacy and safety of POEM in patients with postfundoplication dysfagiaTime frame: 6 months
    Secondary outcomes 10 time frame changed
    What changed in the outcomes
    • Time frameEckardt scoreAt baseline and after 3, 6 and 12 months → At baseline, 3, 6 and 12 months
    • Time frameMellow - Pinkas scoreAt baseline and after 3, 6 and 12 months → At baseline, 3, 6 and 12 months
    • Time framePAGI-QOL score (Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life)At baseline and after 3, 6 and 12 months → At baseline, 3, 6 and 12 months
    • Time frameGERD-RHQL score (Gastroesophageal Reflux Disease Health-related Quality of Life)At baseline and after 3, 6 and 12 months → At baseline, 3, 6 and 12 months
    • Time frameIntegrated Relaxation Pressure (IRP)At baseline and after 6 months → At baseline, at 6 months
    • Time frameEndoluminal planimetry (Endoflip)At baseline and after 6 months → At baseline, ať 6 months
    • Time frameEsophagogramAt baseline and after 6 months → At baseline, at 6 months
    • Time frameEckardt score#2At and after 3 and 12 months → At baseline, 3 and 12 months
    • Time frameGERDAt baseline and after 3, 6 and 12 months → At baseline, 3, 6 and 12 months
    • Time framePPI/H2 antagonistsAt baseline and after 3, 6 and 12 months → At baseline, 3, 6 and 12 months
    + 5 other changes: identifiers, verification date, date precision, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06872255
Lead sponsor
Institute for Clinical and Experimental Medicine
Collaborators
University Hospital Trnava, St. Anne's University Hospital Brno, Czech Republic
Responsible party
Prof. Jan Martinek, MD, PhD, AGAF (Head of Gastroenterology and hepatology department, St. Anne's University Hospital Brno, Czech Republic) — Principal investigator
First posted
Mar 12, 2025
Start date
Apr 1, 2025
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Jan Martínek, prof., MD
Contact
jan.martinek@fnusa.cz
+420 723 708 839
Martin Vašátko, MD
Contact
martin.vasatko@fnusa.cz
+420 739 476 451

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion